Research Article

Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening

Shan-Rong Cai,1 Hong-Hong Zhu,2 Yan-Qin Huang,1 Qi-Long Li,3 Xin-Yuan Ma,3 Su-Zhan Zhang,1 and Shu Zheng1

1Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Science, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China
2Preventive Medicine Institute, Louisiana, MO 63353, USA
3Institute of Oncology Prevention and Treatment, Jiashan, Zhejiang 314100, China

Correspondence should be addressed to Shu Zheng; zhengshu@zju.edu.cn and Hong-Hong Zhu; hozhu@jhsph.edu

Received 11 November 2015; Revised 10 February 2016; Accepted 22 February 2016

Academic Editor: Markus Weber

Copyright © 2016 Shan-Rong Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study investigated the cost-effectiveness between double and single Fecal Immunochemical Test(s) (FIT) in a mass CRC screening. A two-stage sequential screening was conducted. FIT was used as a primary screening test and recommended twice by an interval of one week at the first screening stage. We defined the first-time FIT as FIT1 and the second-time FIT as FIT2. If either FIT1 or FIT2 was positive (+), then a colonoscopy was recommended at the second stage. Costs were recorded and analyzed. A total of 24,419 participants completed either FIT1 or FIT2. The detection rate of advanced neoplasm was 19.2% among both FIT1+ and FIT2+, especially high among men with age ≥55 (27.4%). About 15.4% CRC, 18.9% advanced neoplasm, and 29.9% adenoma missed by FIT1 were detected by FIT2 alone. Average cost was $2,935 for double FITs and $2,121 for FIT1 to detect each CRC and $901 for double FITs and $680 for FIT1 to detect each advanced neoplasm. Double FITs are overall more cost-effective, having significantly higher positive and detection rates with an acceptable higher cost, than single FIT. Double FITs should be encouraged for the first screening in a mass CRC screening, especially in economically and medically underserved populations/areas/countries.

1. Introduction

Colorectal cancer (CRC) is a significant burden on global health [1]. CRC is a leading cause of cancer death worldwide and its incidence and mortality are increasing in China and Japan lately [2]. In China, the overall cumulative incidence of CRC is 28.1 per 100,000 ranking the third in cancer incidence spectrum, 32.3 per 100,000 in urban populations ranking the second, and 35.6 per 100,000 in Jiashan County ranking the first during 2003–2007 [3]. Mass CRC screening is confirmed to be effective in CRC control and prevention, showing a significant decrease of CRC mortality by 15–33% with fecal occult blood tests (FOBT) [4–8]. Many mass CRC screening protocols/strategies in the world have been reported [1, 2, 9]. FOBT, flexible sigmoidoscopy (FS), and colonoscopy are recommended by US for CRC screening [2, 10, II]. However, to date, there is no consistently preferred protocol/strategy of mass CRC screening. Every method has pros and cons [2]. Considering the cost-effectiveness and given that the evidence to date does not suggest a significant difference in cost-effectiveness between the three primary screening tests (FOBT, FS, and colonoscopy) in CRC control and prevention [12, 13], noninvasive and inexpensive FOBT is still a better primary mass CRC screening test than FS and colonoscopy, especially for the economically and medically underserved populations, areas, and countries.

Among all FOBT methods, fecal immunochemical occult blood test (FIT) is recommended by the National Comprehensive Cancer Network, USA [http://www.nccn.org/], and widely accepted in mass CRC screenings. FITs have several improved features compared with the standard guaiac FOBT [2, 13–16]. They are not subject to interference from animal blood in the diet, and they are more sensitive for detection of CRC and advanced adenomas [13–17]. Reported sensitivities
for FIT to detect colorectal neoplasm range from 40.5% to 67% [18–20] and our previous screening result based on natural community populations showed that 9.5% CRC cases were missed by one RPHA-FOBT [21]. Annual FOBT has been reported to reduce more mortality than biennial FOBT (33% versus 18–21%) [2–7]. Thus, to improve the sensitivity in the primary screening, repeated FITs are necessary but how much more cost-effective one additional FIT is than single FIT in a mass screening of CRC remains unclear. This study investigated double FITs of two stool samples collected at different time compared to a single FIT based on cost and effectiveness measures in a free mass CRC screening in a rural population in China.

2. Methods

2.1. Study Design and Population. Permanent residents in Jiashan County, China, were our source population. Our inclusion criteria included all permanent residents who were living in the three randomly selected communities in Jiashan County and aged 40 to 74 years in Gan-Yao in 2007, Da-Yun in 2008, and Yao-Zhuang in 2009. Based on the inclusion criteria, 31,963 permanent residents from these three communities were our study population. All these eligible residents were invited to attend a free CRC screening program. A total of 24,419 study participants signed the written informed consent and participated in this CRC screening program. Basic characteristics of the study participants and positive predictive value of this screening have been reported by Cai et al. [22].

A two-stage sequential screening was designed and conducted. FIT was used as a primary screening test at the first stage of this mass CRC screening. Two stool samples were collected with an interval of one week by community health workers and tested in a local hospital by contracted experienced technicians. Three different parts were taken from each stool sample and then mixed and washed by special buffer solution. Each sample was collected in a bottle, about 5 mL moist stool content. All samples were tested in the laboratory immediately after collection. The second sample was collected in one week after the first one. FIT test using colloidal gold assay (monoclonal antibody) could detect a level of human hemoglobin as low as 0.05 μgHb/mL and be done in less than five minutes. FIT test kits were purchased from WHPM, Inc., in Beijing, China. In this study, we defined the first-time FIT as FIT1, the second-time FIT as FIT2, and either FIT1 or FIT2 as FITs. If any participants have either FIT1 or FIT2 positive (FITs+), then a colonoscopy was recommended at the second stage of screening. Polyethylene Glycol Electrolyte Powder was used as a preparation drug for colonoscopy. If a colonoscopy examination failed due to inadequate bowel preparation or the cecum could not be reached for some reason, a subsequent colonoscopy was performed within one month.

All of the above examinations including FITs and colonoscopy were free to participants. Histopathological examination of CRC, adenoma, and nonadenomatous polyps has been reported by Cai et al. [22]. This study has been reviewed and approved by the Ethics Committee at Zhejiang University Cancer Institute.

2.2. Statistical Analysis. SPSS 16.0 software was used to do data analysis. Positive rate was calculated as the number of positive FITs divided by FIT participants. Detection rate was calculated as the number of detected cases divided by colonoscopy participants. Positive and detection rates in percent, odds ratios (ORs), and 95% confidence intervals (CIs) and the costs in both Renminbi, CNY ($), and US dollars ($) were estimated by FIT and colonoscopy, respectively. Chi-squared tests were used to test the differences in positive and detection rates, and ORs between FIT1, FIT2, and FITs. If more than 20% expected frequencies of the events were below 5 in fourfold (two-by-two frequency) tables, then Fisher’s exact test was used and a rank test was used in multiple contingency tables. Advanced adenoma was defined as adenoma ≥10 mm, or with a histology showing either a ≥20% villous component or high grade dysplasia. Advanced neoplasm was defined as either CRC or advanced adenoma in the analyses.

2.3. Cost Estimation. The cost of FIT1 was CNY ¥8.00 (Renminbi) per case including ¥5.00 for the purchase of test kits, ¥1.50 for sample collection, ¥0.50 for testing fee, and ¥1.00 for test organization. The cost of FIT2 was ¥7.00 per case because the fee for test organization has been done by FIT1. The total cost of colonoscopy was ¥270.00 per case. The currency exchange rate between CNY Yuan and US dollar was ¥6.357 for one USD ($1.00) on August 27, 2012. Other costs such as CRC treatment fees were paid by participants themselves.

3. Results

The overall compliance rate for FITs was 76.4%, with 24,419 participants completing at least one FIT (either FIT1 or FIT2) among the total study population (N = 31,963). The compliance rate was 76.3% (24,375/31,963) for FIT1 and 65.3% (20,886/31,963) for FIT2. A significant lower compliance rate was for FIT2 comparing to that for FIT1 (P < 0.01). The overall compliance rate for colonoscopy was 81.2% (1,430/1,762) among FITs+ participants [22], ranging from 80.7% to 83.1% in any combinations between FIT1 and FIT2. Table 1 presents OR and 95% CI of positive FIT and compliance to colonoscopy by gender, age group, and FIT status in this mass CRC screening program. OR (95% CI) of FITs for the compliance to colonoscopy was 1.03 (0.86–1.25) using FIT1 and 0.92 (0.75–1.13) using FIT2 as reference.

The positive rate was 4.7% (1,148/24,375) by FIT1 and 4.4% (915/20,886) by FIT2. There was no statistical difference in the positive rate between by FIT1 and FIT2 (P > 0.05). The positive rate by either FIT1 or FIT2 was 7.2% significantly higher than that by FIT1 and FIT2, respectively, shown in Table 1. OR (95% CI) of the positive rate by either FIT1 or FIT2 was 1.57 (1.46–1.70) using FIT1 as a reference and 1.70 (1.56–1.84) using FIT2 as a reference. There was no statistical difference in positive rate by either FIT1 or FIT2 between
Table 1: Odds ratio (OR) and 95% confidence interval (CI) of fecal immunochemical test (FIT) positive and compliance to colonoscopy by gender, age group, and FIT status in the Jiashan mass colorectal cancer screening program in China, 2007–2009.

| Gender | Age   | FIT         | Participant n | Positive n (%) | OR1 (95% CI) | OR2 (95% CI) | Colonoscopy n | OR1 (95% CI) | OR2 (95% CI) |
|--------|-------|-------------|---------------|----------------|--------------|--------------|----------------|--------------|--------------|
|        | <55   | FIT1        | 6,435         | 219 (3.4)      | 1.00         | 182 (83.1)   | 1.00           | 182 (83.1)   | 1.00         |
|        |       | FIT2        | 5,314         | 196 (3.7)      | 1.09 (0.89–1.32) | 1.00 | 162 (82.7) | 0.97 (0.58–1.62) | 1.00 |
|        |       | Both        | 5,302         | 62 (1.2)       | 0.34 (0.25–0.45) | 0.31 (0.23–0.41) | 54 (87.3) | 1.37 (0.60–3.12) | 1.42 (1.62–3.23) |
|        |       | Either      | 6,447         | 353 (5.5)      | 1.64 (1.38–1.95) | 1.51 (1.27–1.81) | 294 (83.3) | 1.01 (0.65–1.59) | 1.05 (0.66–1.66) |
|        |       | FIT1        | 5,352         | 327 (6.1)      | 1.00         | 245 (74.9)   | 1.00           | 245 (74.9)   | 1.00         |
|        |       | FIT2        | 4,589         | 253 (5.5)      | 0.90 (0.76–1.07) | 1.00 | 196 (77.5) | 1.15 (0.78–1.70) | 1.00 |
|        |       | Both        | 4,580         | 93 (2.0)       | 0.32 (0.25–0.40) | 0.36 (0.28–0.45) | 73 (78.5) | 1.22 (0.70–2.13) | 1.06 (0.60–1.89) |
|        |       | Either      | 5,361         | 487 (9.1)      | 1.54 (1.33–1.78) | 1.71 (1.46–2.00) | 368 (75.6) | 1.04 (0.75–1.43) | 0.90 (0.63–1.29) |
|        | ≥55   | FIT1        | 6,921         | 297 (4.3)      | 1.00         | 257 (86.5)   | 1.00           | 257 (86.5)   | 1.00         |
|        |       | FIT2        | 5,918         | 224 (3.8)      | 0.88 (0.74–1.05) | 1.00 | 198 (84.4) | 1.54 (0.87–2.72) | 1.00 |
|        |       | Both        | 5,911         | 64 (1.1)       | 0.24 (0.19–0.32) | 0.28 (0.21–0.37) | 57 (89.1) | 1.27 (0.54–2.97) | 1.07 (0.44–2.59) |
|        |       | Either      | 6,928         | 457 (6.6)      | 1.58 (1.36–1.83) | 1.80 (1.52–2.12) | 398 (87.1) | 1.05 (0.68–1.62) | 0.89 (0.54–1.45) |
|        |       | FIT1        | 5,667         | 304 (5.4)      | 1.00         | 237 (78.0)   | 1.00           | 237 (78.0)   | 1.00         |
|        |       | FIT2        | 5,065         | 242 (4.8)      | 0.89 (0.74–1.05) | 1.00 | 198 (81.8) | 1.27 (0.83–1.95) | 1.00 |
|        |       | Both        | 5,049         | 82 (1.6)       | 0.29 (0.23–0.37) | 0.33 (0.26–0.42) | 66 (80.5) | 1.17 (0.63–2.15) | 0.92 (0.49–1.73) |
|        |       | Either      | 5,683         | 464 (8.0)      | 1.57 (1.35–1.82) | 1.77 (1.51–2.08) | 369 (79.5) | 1.10 (0.77–1.56) | 0.86 (0.58–1.28) |
|        | <55   | FIT1        | 11,787        | 547 (4.6)      | 1.00         | 432 (79.0)   | 1.00           | 432 (79.0)   | 1.00         |
|        |       | FIT2        | 9,903         | 449 (4.5)      | 0.98 (0.86–1.11) | 1.00 | 358 (79.7) | 1.05 (0.77–1.43) | 1.00 |
|        |       | Both        | 9,882         | 155 (1.6)      | 0.33 (0.27–0.39) | 0.34 (0.28–0.40) | 127 (81.9) | 1.21 (0.76–1.91) | 1.15 (0.72–1.84) |
|        |       | Either      | 11,808        | 847 (71)       | 1.58 (1.41–1.76) | 1.62 (1.44–1.82) | 663 (78.8) | 0.99 (0.76–1.29) | 0.95 (0.71–1.26) |
|        | ≥55   | FIT1        | 12,588        | 600 (4.8)      | 1.00         | 494 (82.2)   | 1.00           | 494 (82.2)   | 1.00         |
|        |       | FIT2        | 10,983        | 459 (4.2)      | 0.87 (0.77–0.99) | 1.0 | 396 (85.0) | 1.23 (0.88–1.70) | 1.0 |
|        |       | Both        | 10,960        | 145 (1.3)      | 0.27 (0.22–0.32) | 0.31 (0.26–0.37) | 123 (84.2) | 1.16 (0.71–1.89) | 0.95 (0.57–1.58) |
|        |       | Either      | 12,611        | 914 (7.2)      | 1.56 (1.40–1.74) | 1.79 (1.60–2.01) | 767 (83.3) | 1.08 (0.82–1.42) | 0.88 (0.65–2.20) |
|        | All   | FIT1        | 24,937        | 1,148 (4.7)    | 1.0 | 926 (80.7) | 1.0 | 926 (80.7) | 1.0 |
|        |       | FIT2        | 20,886        | 915 (4.4)      | 0.93 (0.85–1.01) | 1.0 | 754 (82.4) | 1.12 (0.90–1.41) | 1.0 |
|        |       | Both        | 20,842        | 301 (1.4)      | 0.30 (0.26–0.34) | 0.32 (0.28–0.37) | 250 (83.1) | 1.18 (0.84–1.64) | 1.05 (0.74–1.48) |
|        |       | Either      | 24,419        | 1,762 (7.2)    | 1.57 (1.46–1.70) | 1.70 (1.56–1.84) | 1,430 (81.2) | 1.03 (0.86–1.25) | 0.92 (0.75–1.13) |

FIT1, the first FIT; FIT2, the second FIT; OR1 using FIT1 as reference; and OR2 using FIT2 as reference.
men and women (71% (841/11,808) among men and 7.2% (914/12,611) among women). The positive rate by either FIT1 or FIT2 was significantly higher among participants with age ≥55 than that among those with age <55 in both genders (9.1% versus 5.5% among men and 8.0% versus 6.6% among women).

There were 39 CRCs and 211 adenomas (88 advanced adenomas and 123 nonadvanced adenomas) patients including 127 advanced neoplasms patients detected by colonoscopy among 1,430 participants with positive FITs. ORs and 95% CIs of detection of CRC and adenoma using colonoscopy as a gold standard by gender, age group, and FIT status are presented in Table 2. ORs of detection of CRC and adenoma by either FIT1 or FIT2 were not statistically significant in all groups whenever FIT1 or FIT2 was used as reference, respectively. But the detection rates of both CRC and adenoma by either FIT1 or FIT2 were shown to be significantly higher among participants with age ≥55 than that among those with age <55 in both genders (OR (95% CI) = 18.63 (2.50–139.05) among men and 3.31 (1.06–10.36) among women). There was no significant difference in detection rate of CRC by FIT1 or FIT2 between men and women. But there was a significant difference in detection rate of adenoma by either FIT1 or FIT2 between men and women. Men had higher detection rates of adenoma in all groups than women. ORs of detection of CRC by both FIT1 and FIT2 were statistically significant in the subgroups of those colonoscopy participants who had both FIT1 and FIT2 positive results (OR = 2.10 (1.16–3.80) using FIT1 as reference and OR = 2.36 (1.26–4.43) using FIT2 as reference) and all men who had both FIT1 and FIT2 positive results (OR = 2.33 (1.03–5.28) using FIT2 as reference), but they were not significant in the subgroups of men with age <55 and age ≥55, women with age <55 and age ≥55, and all women.

Table 3 presents OR and 95% CI of detection of advanced neoplasm by gender, age group, and FIT status. The detection rate of advanced neoplasm by both FIT1 and FIT2 was 19.2%, significantly improved with an OR (95% CI) = 1.90 (1.30–2.76) using FIT1 as reference and 2.25 (1.51–3.35) using FIT2 as reference, so were the rates among all men (1.82 (1.13–2.96) using FIT1 as reference and 2.34 (1.41–3.96) using FIT2 as reference) and all women (1.90 (1.30–2.76) using FIT1 as reference and 2.25 (1.51–3.35) using FIT2 as reference). There was a significant difference in detection of advanced neoplasm by both FIT1 and FIT2 between age <55 and age ≥55 in women but not in men. The detection rate of advanced neoplasm by both FIT1 and FIT2 in men was significantly higher than that in women. In addition, the detection rate of advanced neoplasm was significantly higher among men with age ≥55, men with age ≥55, men with age <55, and women with age ≥55, respectively, than that among women with age <55 in all combinations of FIT1+ and FIT2+.

The detection rates of various colorectal neoplasm by different positive combinations of double FITs are presented in Table 4. There was no significant difference in compliance rate for colonoscopy between two groups with positive FIT1 and FIT2 (P > 0.05). Comparing to FIT1+, the detection rate of CRC by FITs+ was not significantly improved; the detection rate of advanced adenoma by FITs was marginally significantly improved; and the detection rates of nonadvanced adenoma and advanced neoplasm by FITs were significantly improved (OR (95% CI) = 1.58 (1.19–2.10) and 1.38 (1.07–1.80), resp.). The detection rates were increased about 38% for advanced neoplasm and 58% for nonadvanced adenoma (45% for colorectal neoplasm) by FITs compared to FIT1 alone. There were 61.5% (24/39) CRC cases detected at an early stage (T1,N0,M0). Additional 15.4% (6/39, and among 6, 66.7% (4/6) were detected at an early stage) CRC, 20.5% advanced adenoma, 35.8% nonadvanced adenoma, and 18.9% advanced neoplasm cases missed by FIT1 were detected by FIT2 alone.

Costs in both Chinese Renminbi, CNY (¥), and US dollar ($) and detected CRC and advanced neoplasm by comparing double FITs to single FIT are presented in Table 5. Costs for the detection of CRC and advanced neoplasm by double FITs based on ¥8.00 ($1.22) for FIT1 and ¥7.00 ($1.07) for FIT2 per participant, respectively, were increased about 33–38%, $2,955 for double FITs and $2,121 for FIT1 for CRC and $901 for double FITs and $680 for FIT1 for advanced neoplasm. FIT2 found additional 6 CRC and 24 advanced neoplasm cases with an acceptable average cost of $7,401 and $1,850, respectively.

4. Discussion

This study investigated the performance of double FITs comparing to single FIT in a mass CRC screening in a rural population in China. The major findings indicated that double FITs were overall more cost-effective than single FIT. The positive rate was improved by double FITs comparing to FIT1 or FIT2 alone. The compliance rate for colonoscopy between FIT1 and FIT2 was similar. The detection rate of advanced neoplasm by double FITs was significantly improved comparing to FIT1. Double FITs found 18% more CRC and 38% more colorectal advanced neoplasms than single FIT. A total of 15.4% (6/39) CRC, 18.9% advanced neoplasm, and 29.9% adenoma (including 20.5% advanced adenoma and 35.8% nonadvanced adenoma) detected by FIT2 alone would have been missed if only FIT1 had been used in the primary screening. The cost for CRC and advanced neoplasm detected by double FITs was increased about 33–38% which is acceptable and inexpensive comparing to 30 (6 CRC and 24 advanced neoplasm cases) lives saved from dying of colorectal advanced neoplasm cases and hundreds of other colorectal lesions cases prevented from developing CRC detected by FIT2 alone.

Some people in the community feel inconvenient and uncomfortable to collect stool samples, but stool samples are easily accessible and transportable, involving no painful procedure for collection, and can be done in privacy at home. Studies show that serum biomarkers such as M2PK and carcinoembryonic antigen (CEA) and/or combinations of these biomarkers could be a promising primary screening test in mass CRC screening [1, 2] but larger prospective studies using study populations representing a screening population are needed to verify promising results [23]. Serum CEA alone may not be a good screening test and it may be a little bit more expensive than FIT though it has been
## Table 2: Odds ratio (OR) and 95% confidence interval (CI) of detection of colorectal cancer (CRC) and adenoma using colonoscopy as a gold standard by gender, age group, and fecal immunochemical test (FIT) status in the Jiashan mass CRC screening program in China, 2007–2009.

| Gender/age | FIT | Colonoscopy participant | CRC n (%) | OR1 (95% CI) | OR2 (95% CI) | OR3 (95% CI) | Adenoma n (n%), % | OR1 (95% CI) | OR2 (95% CI) | OR3 (95% CI) |
|------------|-----|-------------------------|-----------|---------------|---------------|---------------|-----------------|---------------|---------------|---------------|
| **Men**   |     |                         |           |               |               |               |                 |               |               |               |
| <55       | FIT1 | 257                     | 3 (75.0)  | 1.00          | 1.00          | 1.00          | 18 (81.3)      | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
|           | FIT2 | 198                     | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 237 (83.3)     | 1.00          | 1.00          | 1.00          |
|           | Both | 57                      | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 257 (80.0)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
|           | Either | 398                   | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 398 (82.8)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
| ≥55       | FIT1 | 245                     | 19 (86.4) | 1.00          | 1.00          | 1.00          | 257 (83.3)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
|           | FIT2 | 198                     | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 257 (80.0)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
|           | Both | 57                      | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 398 (82.8)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
|           | Either | 398                   | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 398 (82.8)     | 1.00          | 0.56 (0.27–1.133) | 102 (75)      | 1.00          |
| **Women** |     |                         |           |               |               |               |                 |               |               |               |
| <55       | FIT1 | 237                     | 10 (83.3) | 1.00          | 1.00          | 1.00          | 127 (43.8)     | 1.00          | 1.00          | 1.00          |
|           | FIT2 | 198                     | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 127 (43.8)     | 1.00          | 1.00          | 1.00          |
|           | Both | 57                      | 1 (25.0)  | 1.00          | 1.00          | 1.00          | 257 (78.0)     | 1.00          | 1.00          | 1.00          |
|           | Either | 398                   | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 398 (79.3)     | 1.00          | 1.00          | 1.00          |
| ≥55       | FIT1 | 237                     | 10 (83.3) | 1.00          | 1.00          | 1.00          | 237 (83.3)     | 1.00          | 1.00          | 1.00          |
|           | FIT2 | 198                     | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 237 (83.3)     | 1.00          | 1.00          | 1.00          |
|           | Both | 57                      | 1 (25.0)  | 1.00          | 1.00          | 1.00          | 398 (82.8)     | 1.00          | 1.00          | 1.00          |
|           | Either | 398                   | 0 (0.0)   | 0.00          | 0.00          | 0.00          | 398 (82.8)     | 1.00          | 1.00          | 1.00          |
| **Total** |     |                         |           |               |               |               |                 |               |               |               |
| FIT1      | 494 | 13 (81.3)               | 1.00      | 0.56 (0.27–1.133) | 46 (25)       | 1.00          |
| FIT2      | 396 | 10 (62.5)               | 1.00      | 0.64 (0.28–1.45) | 44 (19)       | 1.00          |
| Both      | 123 | 7 (43.8)                | 1.00      | 0.64 (0.24–1.74) | 18 (10)       | 1.00          |
| Either    | 767 | 16 (100)                | 1.00      | 0.59 (0.31–1.13) | 72 (34)       | 1.00          |

FIT1, the first FIT; FIT2, the second FIT; OR1 using FIT1 as reference and OR2 using FIT2 as reference; OR3 using men with age <55 who completed FIT1 as reference, OR3 using men with age <55 who completed both FIT1 and FIT2 as reference, OR3 using men with age <55 who completed either FIT1 or FIT2 as reference, OR3 using women with age <55 who completed FIT1 as reference, OR3 using women with age <55 who completed FIT2 as reference, OR3 using women with age <55 who completed both FIT1 and FIT2 as reference, and OR3 using women with age <55 who completed either FIT1 or FIT2 as reference.

n∗: the number of advanced adenomas.
Table 3: Odds ratio (OR) and 95% confidence interval (CI) of detection of advanced neoplasm using colonoscopy as a gold standard by gender, age group, and fecal immunochemical test (FIT) status in the Jiaoshan mass colorectal cancer screening program in China, 2007–2009.

| Gender | Age | FIT Colonscopy participant | Advanced neoplasm n (%) | OR1 (95% CI) | OR2 (95% CI) | OR3 (95% CI) |
|--------|-----|---------------------------|-------------------------|--------------|--------------|--------------|
|        |     | FIT1                       | 182                     | 23 (12.6)    | 1.0          | 1.0          |
|        |     | FIT2                       | 162                     | 15 (9.3)     | 0.71 (0.35–1.40) | 1.0          | 1.0          |
|        |     | Both                       | 54                      | 11 (20.4)    | 1.77 (0.80–3.91) | 2.51 (1.07–5.86) | 1.0          |
|        |     | Either                     | 294                     | 27 (9.2)     | 0.70 (0.39–1.26) | 0.99 (0.53–1.92) | 1.0          |
| Men    | <55 | FIT1                       | 245                     | 42 (17.1)    | 1.0          | 1.43 (0.83–2.48) |
|        |     | FIT2                       | 196                     | 28 (14.3)    | 0.81 (0.48–1.36) | 1.0          | 1.63 (0.84–3.18) |
|        |     | Both                       | 73                      | 20 (27.4)    | 1.82 (0.99–3.37) | 2.26 (1.18–4.34) | 1.48 (0.64–3.41) |
|        |     | Either                     | 368                     | 50 (13.6)    | 0.76 (0.49–1.19) | 0.94 (0.57–1.55) | 1.56 (0.95–2.55) |
| Women  | <55 | FIT1                       | 257                     | 11 (4.3)     | 1.0          | 1.0          |
|        |     | FIT2                       | 198                     | 7 (3.5)      | 0.82 (0.31–2.15) | 1.0          | 1.0          |
|        |     | Both                       | 57                      | 4 (7.0)      | 1.69 (0.52–5.51) | 2.06 (0.59–7.30) | 1.0          |
|        |     | Either                     | 398                     | 14 (3.5)     | 0.82 (0.36–1.83) | 1.0 (0.40–2.51) | 1.0          |
| Men    | ≥55 | FIT1                       | 237                     | 27 (11.4)    | 1.0          | 2.88 (1.39–5.94) |
|        |     | FIT2                       | 198                     | 22 (11.1)    | 0.97 (0.54–1.77) | 1.0          | 3.41 (1.42–8.18) |
|        |     | Both                       | 66                      | 13 (19.7)    | 1.91 (0.92–3.95) | 1.96 (0.93–4.16) | 3.25 (1.00–10.61) |
|        |     | Either                     | 369                     | 36 (9.8)     | 0.84 (0.50–1.43) | 0.87 (0.49–1.52) | 2.97 (1.57–5.59) |
| Women  | ≥55 | FIT1                       | 432                     | 65 (15.0)    | 1.0          | 1.0          |
|        |     | FIT2                       | 358                     | 43 (12.0)    | 0.77 (0.51–1.17) | 1.0          | 1.0          |
|        |     | Both                       | 127                     | 31 (24.4)    | 1.82 (1.13–2.96) | 2.34 (1.41–3.96) | 1.0          |
|        |     | Either                     | 663                     | 77 (11.6)    | 0.74 (0.52–1.06) | 0.96 (0.65–1.43) | 1.0          |
| Men    | All | FIT1                       | 494                     | 38 (7.7)     | 1.0          | 0.47 (0.31–0.72) |
|        |     | FIT2                       | 396                     | 29 (7.3)     | 0.95 (0.57–1.57) | 1.0          | 0.58 (0.35–0.95) |
|        |     | Both                       | 123                     | 17 (11.4)    | 1.93 (1.05–3.54) | 2.03 (1.07–3.84) | 0.50 (0.26–0.95) |
|        |     | Either                     | 767                     | 56 (7.3)     | 0.95 (0.62–1.45) | 1.00 (0.63–1.59) | 0.60 (0.42–0.86) |
| Women  | All | FIT1                       | 926                     | 103 (11.1)   | 1.0          | —            |
|        |     | FIT2                       | 754                     | 72 (9.5)     | 0.84 (0.61–1.16) | 1.0          | —            |
|        |     | Both                       | 250                     | 48 (19.2)    | 1.90 (1.30–2.76) | 2.25 (1.51–3.35) | —            |
|        |     | Either                     | 1,430                   | 127 (8.9)    | 0.78 (0.59–1.02) | 0.92 (0.68–1.25) | —            |

FIT1, the first FIT; FIT2, the second FIT; OR1 using FIT1 as reference and OR2 using FIT2 as reference; OR3 using men with age <55 who completed FIT1 as reference, OR3 using men with age <55 who completed FIT2 as reference, OR3 using men with age <55 who completed both FIT1 and FIT2 as reference, OR3 using men with age <55 who completed either FIT1 or FIT2 as reference, OR3 using women with age <55 who completed FIT1 as reference, OR3 using women with age <55 who completed FIT2 as reference, OR3 using women with age <55 who completed both FIT1 and FIT2 as reference, and OR3 using women with age <55 who completed either FIT1 or FIT2 as reference.

Widely used in the surveillance of patients following primary surgical resection of CRC [24, 25] but it may be possible to be used as one of primary screening tests combining with other biomarkers such as FIT in mass screenings. Due to our limited budget, no serum biomarkers were used as primary screening in this mass CRC screening.

Overall, FOBT is relatively easy, safe, inexpensive, and acceptable comparing to colonoscopy which is limited by high cost, low participation rate, and variation in performance according to the endoscopist and high risk of pain and other adverse side effects [1, 2, 26–28]. Therefore, FOBT is still the first choice as a primary screening test for mass screening in many countries [16], especially in economically and medically underserved populations and areas [2, 7, 9]. Among all FOBTs, FIT is the most popular and acceptable primary screening test for its low cost and accessibility and a high adherence and detection rate of colorectal neoplasm [15, 16, 29] in mass CRC screening.

Sobhani has reported that screening program using FITs with three samples collected from three different parts of one-time stool at the same time is cost-effective [30]. But one sample for three FITs cost more than double FITs and may miss colorectal lesions with intermittent bleeding. Based on our decades' experience of mass CRC screening programs, the second FIT in one week after the first one is much easier to complete than that in one or two year(s) with a relatively lower cost without additional cost for organization and encouragement fees when the first FIT is completed. In addition, FITs with two stool samples collected at different time increase the detection rate of bleeding and may help detect those tumors with intermittent bleeding that may be missed by single FIT. Few studies, however, have been done...
Table 4: Odds ratio (OR) and 95% confidence interval (CI) of detection of various colorectal neoplasm using colonoscopy as a gold standard by different positive combinations of double fecal immunochemical tests (FITs) in the Jiashan mass colorectal cancer (CRC) screening program in China, 2007–2009.

| FIT1 | FIT2 | FITs | Positive Colonoscopy | Results: n, detection rate, percentage<sup>a</sup> |
|------|------|------|----------------------|-----------------------------------------------|
|      |      | FITs | n | n | n | CRC | Advanced adenoma | Nonadvanced adenoma | Advanced neoplasm |
| +    | −    | 20,842 | 763 | 619 | 12,1,30.1 | 37, 6.0, 42.0 | 49,79, 39.8 | 49,79, 38.6 |
| +    | +    | 20,842 | 301 | 250 | 18,1,46.2 | 30, 12.0, 34.1 | 24, 9.6, 19.5 | 48,19, 37.8 |
| +    | Absent | 3,533 | 84 | 57 | 3,5,7.7 | 3, 5.3, 3.4 | 5,8.8, 4.1 | 6,7.1, 4.7 |
| −    | +    | 20,842 | 609 | 500 | 6,1,15.4 | 18,3,20.5 | 44,8.8, 35.8 | 24,4.8, 18.9 |
| Absent | 44 | 5 | 4 | 0 | 1 | 0 | 1.25,0.5 | 0 |

FIT1+, referred to those who completed FIT1 regardless of the completion of FIT2.

FIT2+, referred to those who completed FIT2 regardless of the completion of FIT1.

Table 5: Costs in both Chinese Renminbi, CNY (¥), and US dollar ($) and detected colorectal cancer (CRC) and advanced neoplasm by comparing double FITs to single FIT in the Jiashan mass CRC screening program in China, 2007–2009.

| FIT | Colonoscopy | CRC | Advanced neoplasm |
|-----|-------------|-----|-------------------|
|     | Participant | Total cost (¥/$)<sup>a</sup> | Positive Participant | Total cost (¥/$)<sup>a</sup> | Number | Cost (¥/$)<sup>a</sup>/case | Number | Cost (¥/$)<sup>a</sup>/case |
| FIT1 | 24,375 | 195,000/30,675 | 1,148 | 926 | 250,020/39,330 | 33 | 13,485/2,121 | 103 | 4,321/680 |
| FIT2 | 20,886 | 146,202/22,999 | 915 | 754 | 203,580/32,025 | 24 | 14,574/2,293 | 72 | 4,858/764 |
| Both | 20,842 | 312,603/49,179 | 301 | 250 | 67,500/10,618 | 18 | 21,118/3,322 | 48 | 7,919/1,246 |
| Either | 24,419 | 341,510/53,722 | 1,762 | 1,430 | 386,100/60,736 | 39 | 18,657/2,935 | 127 | 5,729/901 |
| FIT2 only | 20,886 | 146,202/22,999 | 614 | 504 | 136,080/21,406 | 6 | 47,047/7,401 | 24 | 11,762/1,850 |

FIT1, the first FIT; FIT2, the second FIT; FITs, combination of FIT1 and FIT2.

The detection rate of advanced neoplasm and nonadvanced adenoma was significantly improved by 38–58% in double FITs+ compared to that in FIT1+. The detection rates of CRC and advanced adenoma were not significantly improved maybe due to a small number of CRC and advanced adenoma cases being detected. If the mass screening is applied among a larger population, the detection rates of both CRC and advanced adenoma would be significantly improved.

In our study, a total of 61.5% (24/39) CRC cases were detected at an early stage (T<sub>1</sub>, N<sub>0</sub>, M<sub>0</sub>) and 88 colorectal advanced adenoma cases were detected in this screening protocol. Thus, 88.2% (= (24+88)/127) colorectal advanced neoplasm cases detected by screening were at an early stage of colorectal lesions. That is to say, these cases’ lives were saved from dying of CRC after they received timely treatment and are getting more benefits from this screening for the rest of their life. A total of 15.4% CRC, 18.9% advanced neoplasm, and 29.9% adenoma (including 20.5% advanced adenoma and 35.8% nonadvanced adenoma) detected by FIT2 would have been missed if only FIT1 screening had been used.
Double FITs found 18% more CRC and 38% more colorectal advanced neoplasms than single FIT1. The cost for CRC and advanced neoplasm detected by double FITs was increased about 33–38% which is acceptable because a FIT screening cost is about CNY ¥8.00 per person in China, equivalently about US $1.22 per person. The average cost was $2,935 for double FITs and $2,121 for FIT1 for CRC and $901 for double FITs and $680 for FIT1 for 108 advanced neoplasm cases. A total of $7,401 and $1,850 was the cost for additional six CRC and 24 advanced neoplasm cases by FIT2 only. But our study design of two FITs by an interval of one week saves additional 14.3% costs from FIT2 which costed ¥7.00 per participant comparing to ¥8.00 for FIT1. It would save millions of dollars in mass screenings if this screening protocol is used in China. Therefore, we deduce that double FITs by an interval of one week at the first stage is more cost-effective than single FIT in mass colorectal screenings in China, especially in medically and economically underserved populations, areas, and countries.

This study has some strengths. This is a large mass screening in a rural population in China. The compliance rate is relatively high. Our study design of two FITs by an interval of one week at the first screening stage can (1) help detect some colorectal lesions with intermittent bleeding which one FIT and two or more FITs from one sample may miss and the second FIT in one or two year(s) may be too late to diagnose, (2) save additional costs such as screening organization fees, and (3) increase compliance to the second FIT in one week. The cost analysis is based on the actual spent dollars and a comparative analysis between double FITs and single FIT within this screening program. The future benefits from this screening have not been included. Overall, results from this screening are reliable and valid. There are some limitations in this study. Some nonbleeding colorectal lesions may be missed due to the default of FOBT. False negative and false positive rates are relatively high because FITs have a relatively low sensitivity and specificity FIT comparing to colonoscopy.

5. Conclusions

Double FITs are more cost-effective than single FIT in our mass CRC screening based on the evidence of having significantly higher positive and detection rates with an acceptable higher cost by double FITs than single FIT. Double FITs should be encouraged for the first screening in a mass CRC screening, especially in economically and medically underserved populations/areas/countries.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Shan-Rong Cai and Hong-Hong Zhu equally contributed to the work.

Acknowledgments

This study was supported by the China National 11th Five-Year Scientific Project (Grant no. 2006BA2A08) and a Special Fund to the Local Public Health by the China National Fiscal Supplement—National Cancer Early Detection and Treatment Program (2006–2009, Ministry of Health, Ministry of Finance, China), and Zhejiang Medical and health science and technology project (2013KYA091). The authors thank the members of the China National Committee of Cancer Early Detection and Treatment and all general practitioners in the study communities, and doctors and nurses of the local hospitals in the study population including Gan-Yao, Da-Yun, and Yao-Zhuang communities in Jia-Shan County. Also, the authors are thankful for the support from the Board of Health in Jia-Shan County and community workers involved in this study.

References

[1] H. H. Zhu, "Perspectives of mass colorectal cancer screening and early clinical diagnosis," Journal of GHR, vol. 2, no. 5, pp. 564–567, 2013.
[2] H. H. Zhu and S. Zheng, "Sequential combination of serum pyruvate kinase isoenzyme M2 and colonoscopy-a promising screening protocol for CRC Early diagnosis," Journal of Biosensors and Bioelectronic, vol. S2, pp. 2–9, 2011.
[3] P. Zhao, W. Q. Chen, and L. Z. Kong, Cancer Incidence and Mortality in China, 2003–2007, Military Medical Science Press, 2012.
[4] J. D. Hardcastle, J. O. Chamberlain, M. H. E. Robinson et al., "Randomised controlled trial of faecal-occult-blood screening for colorectal cancer," The Lancet, vol. 348, no. 9040, pp. 1472–1477, 1996.
[5] O. Kronborg, C. Fenger, J. Olsen, O. D. Jørgensen, and O. Sondergaard, "Randomised study of screening for colorectal cancer with faecal-occult-blood test," The Lancet, vol. 348, no. 9040, pp. 1467–1471, 1996.
[6] J. S. Mandel, J. H. Bond, T. R. Church et al., "Reducing mortality from colorectal cancer by screening for fecal occult blood," The New England Journal of Medicine, vol. 328, no. 19, pp. 1365–1371, 1993.
[7] S. Zheng, K. Chen, X. Liu et al., "Cluster randomization trial of sequence mass screening for colorectal cancer," Diseases of the Colon and Rectum, vol. 46, no. 1, pp. 51–58, 2003.
[8] A. G. Zauber and I. Lansdorp-Vogelaar, "Changes in risk factors and increases in screening contribute to the decline in colorectal cancer mortality, 1975 to 2000," Gastroenterology, vol. 139, no. 2, p. 698, 2010.
[9] Z. F. Gellad and D. Provenzale, "Colorectal Cancer: national and international perspective on the burden of disease and public health impact," Gastroenterology, vol. 138, no. 6, pp. 2177–2190, 2010.
[10] M. Brethauer, "Evidence for CRC screening," Best Practice & Research. Clinical Gastroenterology, vol. 24, no. 4, pp. 417–425, 2010.
[11] J. B. M. J. Jansen, "Flexible sigmoidoscopy to prevent colorectal cancer," The Lancet, vol. 376, no. 9744, pp. 870–871, 2010.
[12] J. Regula, M. Rupinski, E. Kraszewksa et al., “Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia,” *The New England Journal of Medicine*, vol. 355, no. 18, pp. 1863–1872, 2006.

[13] T. R. Church, “Screening for CRC—which strategy is the best?” *Journal of the National Cancer Institute*, vol. 103, no. 17, pp. 1282–1283, 2011.

[14] T. R. de Wijkerslooth, P. M. Bossuyt, and E. Dekker, “Strategies in screening for colon carcinoma,” *Netherlands Journal of Medicine*, vol. 69, no. 3, pp. 112–119, 2011.

[15] D. Cunningham, W. Atkin, H.-J. Lenz et al., “Colorectal cancer,” *The Lancet*, vol. 375, no. 9719, pp. 1030–1047, 2010.

[16] M. M. Zhu, X. T. Xu, F. Nie, J. L. Tong, S. D. Xiao, and Z. H. Ran, “Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis,” *Journal of Digestive Diseases*, vol. 11, no. 3, pp. 148–160, 2010.

[17] J. E. Allison, L. C. Sakoda, T. R. Levin et al., “Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics,” *Journal of the National Cancer Institute*, vol. 99, no. 19, pp. 1462–1470, 2007.

[18] G. D. Launoy, H. J. Bertrand, C. Berchi et al., “Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population,” *International Journal of Cancer*, vol. 115, no. 3, pp. 493–496, 2005.

[19] Z. Levi, P. Rozen, R. Hazazi et al., “A quantitative immunochemical fecal occult blood test for colorectal neoplasia,” *Annals of Internal Medicine*, vol. 146, no. 4, pp. 244–255, 2007.

[20] F. A. Oort, J. S. Terhaar Sive Droste, R. W. M. Van Der Hulst et al., “Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test,” *Alimentary Pharmacology and Therapeutics*, vol. 31, no. 3, pp. 432–439, 2010.

[21] S. Zheng, J. M. Wu, R. B. Zhou et al., “Asymptomatic colorectal cancer screening in China,” *Chinese Medical Journal*, vol. 71, no. 7, pp. 381–384, 1991.

[22] S. R. Cai, S. Z. Zhang, H. H. Zhu et al., “Performance of a colorectal cancer screening protocol in an economically and medically underserved population,” *Cancer Prevention Research*, vol. 4, no. 10, pp. 1572–1579, 2011.

[23] S. Hundt, U. Haug, and H. Brenner, “Blood markers for early detection of colorectal cancer: a systematic review,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 16, no. 10, pp. 1935–1953, 2007.

[24] G. Y. Locker, S. Hamilton, J. Harris et al., “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer,” *Journal of Clinical Oncology*, vol. 24, no. 33, pp. 5313–5327, 2006.

[25] R. C. Langan, J. E. Mullinax, M. T. Raij et al., “Colorectal cancer biomarkers and the potential role of cancer stem cells,” *Journal of Cancer*, vol. 4, no. 3, pp. 241–250, 2013.

[26] L. Hol, V. de Jonge, M. E. van Leerdam et al., “Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy,” *European Journal of Cancer*, vol. 46, no. 11, pp. 2059–2066, 2010.

[27] D. Lieberman, “Progress and challenges in CRC screening and surveillance,” *Gastroenterology*, vol. 138, no. 6, pp. 2115–2126, 2010.

[28] L. Guittet, “Screening for CRC,” *The New England Journal of Medicine*, vol. 362, p. 2, 2010.